Oliver Wyman has named Darshan Vora a partner in its London wing. He brings more than a decade of strategy consulting experience to the firm’s health and life sciences sector, and private capital teams.
Global strategy and management consulting firm Oliver Wyman grew its global revenues by 9% over the past year to $3.4 billion. As the consulting firm looks to build on that success for the year ahead, it has commenced 2025 with a number of new promotions and appointments.
The latest of these sees Darshan Vora become the partner for Oliver Wyman’s healthcare, life sciences and private capital practices. Based in London, he brings to the role more than 15 years of strategy consulting experience, in the health and life sciences sector, focusing on transaction advisory, commercial, and research and development strategy.
Commenting on the arrival, Chris McMillan, head of private capital for Europe, said, “We’re delighted to welcome Darshan back to the private capital team. His depth deep understanding of health and life sciences, and expertise in a range of deal and value creation capabilities will further enhance our fast-growing practice and deliver breakthrough value for clients.”
Having started his career with a five year stint at Oliver Wyman, Vora joined Kearney in 2016, before becoming a partner with EY-Parthenon in 2022. He rejoins Oliver Wyman, with a proven track record of collaborating with leading investors and large pharmaceutical corporations, delivering significant value across the healthcare sector.
Vora added, “It’s rewarding to work in such a dynamic and innovative sector, knowing that my efforts not only unlock growth and commercial value for my clients but also contribute to improving patient outcomes and people’s lives as a whole.”